Protein Information

ID 75
Name albumin
Synonyms ALB; Albumin; PRO0883; PRO0903; PRO1341; PRO1708; PRO2044; PRO2619…

Compound Information

ID 1779
Name phosphorus
CAS phosphorus

Reference

PubMed Abstract RScore(About this table)
20336459 Shinjo SK, Bonfa E, de Falco Caparbo V, Pereira RM: Low bone mass in juvenile onset sclerosis systemic: the possible role for 25-hydroxyvitamin D insufficiency. Rheumatol Int. 2010 Mar 25.
Juvenile onset systemic sclerosis (JoSSc) is a rare disease, and there are no studies focusing in bone mineral density and biochemical bone parameters. Ten consecutive patients with JoSSc and 10 controls gender, age, menarche age, and physical activity matched were selected. Clinical data were obtained at the medical visit and chart review. Laboratorial analysis included autoantibodies, 25-hydroxyvitamin D (25OHD), intact parathyroid hormone, calcium, phosphorus, alkaline phosphatase and albumin sera levels. Bone mineral density was analyzed by dual-energy X-ray absorptiometry, and bone mineral apparent density (BMAD) was calculated. A lower BMAD in femoral neck (0.294 +/- 0.060 vs. 0.395 +/- 0.048 g/cm (3), P = 0.001) and total femur (0.134 +/- 0.021 vs. 0.171 +/- 0.022 g/cm (3), P = 0.002) was observed in JoSSc compared to controls. Likewise, a trend to lower BMAD in lumbar spine (0.117 +/- 0.013 vs. 0.119 +/- 0.012 g/cm (3), P = 0.06) was also found in these patients. Serum levels of 25OHD were significantly lower in JoSSc compared to controls (18.1 +/- 6.4 vs. 25.1 +/- 6.6 ng/mL, P = 0.04), and all patients had vitamin D insufficiency (<20 ng/mL) compared to 40% of controls (P = 0.01). All other biochemical parameters were within normal range and alike in both groups. BMAD in femoral neck and total femur was correlated with 25OHD levels in JoSSc (r = 0.82, P = 0.004; r = 0.707, P = 0.02; respectively). We have identified a remarkable high prevalence of 25OHD insufficiency in JoSSc. Its correlation with hip BMAD suggests a causal effect and reinforces the need to incorporate this hormone evaluation in this disease management.
6(0,0,1,1)